BioCentury
ARTICLE | Clinical News

GSK961081: Phase IIb data

May 28, 2012 7:00 AM UTC

A double-blind, placebo- and active-controlled, international Phase IIb trial in 436 patients with moderate to severe COPD showed that all doses of GSK961081 met the primary endpoint of improving mean...